Authored by: Sriram Chakravadhanula Art by: Carol Zhang In March 2024, the U.S. Food and Drug Administration (FDA) approved GLP-1 medication for heart disease, in addition to its application for diabetes, leading to a massive increase in GLP-1 users. The United States became the largest market for Ozempic and Wegovy supplier, Novo Nordisk, with over 71% of the Company’s drug sales come from the United States[1]. As Senator Warren revealed, Ozempic is priced at $936 in the US, compared to a...